title: Role of surgery following induction therapy for stage III non-small cell lung cancer.
abstract: Over the last 30 years neoadjuvant treatment of stage IIIA non-small cell lung cancer (NSCLC) followed by surgical resection for stage IIIB disease has significantly improved the overall results of treatment for patients with stage III NSCLC as well as for those with locally invasive tumors. Different chemotherapy regimens have been used, although in most studies some combination of drugs that include cisplatin is the standard. Radiation when given as part of the induction protocol appears to offer a higher rate of resection and complete resection, and higher doses of radiation are associated with better nodal downstaging. Resection in patients with persistent N2 disease and pneumonectomy following induction therapy remain controversial. Resection in patients with persistent N2 disease and pneumonectomy following induction therapy remain controversial.
authors: Cardiothoracic Surgery Boston Medical Center, 88 East Newton Street Robinson B402, Boston, MA 02118, USA. benedict.daly@bmc.org
authors: Benedict D T
authors: BD
authors: Daly
authors: Robert J
authors: RJ
authors: Cerfolio
authors: Mark J
authors: MJ
authors: Krasna
mesh_terms: D000970:Antineoplastic Agents / Q000627:therapeutic use*; D002289:Carcinoma, Non-Small-Cell Lung / Q000188:drug therapy / Q000601:surgery*; D003131:Combined Modality Therapy; D006801:Humans; D008175:Lung Neoplasms / Q000188:drug therapy / Q000601:surgery*; D009367:Neoplasm Staging; D011379:Prognosis; D012074:Remission Induction
chemical_list: D000970:Antineoplastic Agents